Interim injunction standards in pharma launches

Introduction

Interim injunctions in pharmaceutical launches are temporary judicial orders issued to prevent a party from carrying out certain activities until a legal dispute is finally decided. In the pharmaceutical industry, such injunctions commonly arise in patent infringement, trademark disputes, manufacturing conflicts and unauthorised commercialisation of medicines.

A pharmaceutical launch involves substantial investment in research, manufacturing, regulatory approvals, marketing and distribution. If a generic manufacturer launches a medicine allegedly infringing an existing patent, the patent holder may approach a court seeking an interim injunction. Similarly, a generic manufacturer may challenge an injunction that prevents access to an affordable medicine.

Indian courts must balance intellectual property protection, commercial interests, public health and patients' access to essential medicines.

Legal framework governing interim injunctions

The principal legal framework for interim injunctions in India is provided by the Code of Civil Procedure, 1908.

1. Order XXXIX Rules 1 and 2

These provisions empower courts to grant temporary injunctions where property or legal rights are threatened during litigation. In pharmaceutical disputes, they may prevent manufacturing, marketing, selling or distributing an allegedly infringing medicine.

2. Section 151 of the Code of Civil Procedure, 1908

This provision preserves the inherent powers of courts to make orders necessary for the ends of justice or to prevent abuse of judicial process.

3. Patents Act, 1970

Section 48 provides exclusive rights to patent holders. Section 107 allows certain grounds of defence in infringement proceedings, including grounds on which a patent may be revoked under Section 64.

Section 83 also establishes general principles governing the exercise of patent rights, including the importance of public health and the availability of patented inventions at reasonably affordable prices.

4. Specific Relief Act, 1963

Sections 36 and 37 address preventive relief through injunctions. These provisions operate alongside the procedural requirements under the Code of Civil Procedure.

Essential standards for granting interim injunctions

Indian courts generally apply three established requirements before granting an interim injunction.

1. Prima facie case

The applicant must demonstrate a genuine legal claim requiring judicial protection. In pharmaceutical patent disputes, the court examines patent validity, ownership, infringement allegations and the available technical evidence.

A registered patent does not automatically guarantee an interim injunction. The court may examine whether the patent appears vulnerable to a substantial validity challenge.

2. Balance of convenience

The court considers which party would suffer greater hardship if the injunction is granted or refused.

For example, stopping a pharmaceutical launch may cause substantial commercial losses to a generic manufacturer. However, permitting an allegedly infringing launch may damage the patent holder's exclusive rights and market position.

3. Irreparable injury

The applicant must demonstrate that damages or other remedies may not adequately compensate for the harm caused by refusing the injunction. Loss of market exclusivity, reputational damage and disruption of established commercial arrangements may be relevant considerations.

These three requirements must generally be considered together rather than independently.

Special considerations in pharmaceutical launches

Pharmaceutical disputes require additional attention because medicines directly affect public health.

1. Public interest: Courts examine whether an injunction could restrict access to essential or affordable medicines.

2. Patent validity: Pharmaceutical patents may face challenges involving novelty, inventive step, insufficient disclosure and Section 3(d) of the Patents Act.

3. Regulatory approval: Regulatory permission to manufacture or sell a medicine does not automatically establish freedom from patent infringement.

4. Generic competition: Courts consider the consequences of restricting generic competition, particularly where the medicine concerns serious or life-threatening diseases.

5. Delay and conduct: Unexplained delay in seeking an injunction, incomplete disclosure or misleading representations may influence judicial discretion.

Important judicial decisions

1. Wander Ltd. v. Antox India (P) Ltd. (1990) Supp SCC 727

The Supreme Court explained the principles governing interim injunctions and emphasised that appellate courts should not interfere casually with the discretionary decisions of trial courts. The judgment remains an important authority on prima facie case, balance of convenience and irreparable injury.

2. F. Hoffmann-La Roche Ltd. v. Cipla Ltd. (2008) 148 DLT 598

The Delhi High Court considered a pharmaceutical patent dispute involving the cancer medicine Erlotinib. The court examined patent infringement, validity challenges, balance of convenience and public interest while refusing the requested interim injunction at that stage.

The decision is particularly important because it demonstrates that pharmaceutical patent disputes require careful consideration of competing commercial and public health interests.

3. Merck Sharp & Dohme Corporation v. Glenmark Pharmaceuticals Ltd. (2015) 63 PTC 257 (Del)

The Delhi High Court dealt with a dispute concerning the diabetes medicine Sitagliptin. It examined patent infringement and the requirements for interim relief. The decision illustrates the importance of evaluating patent claims, technical evidence and the competing interests of pharmaceutical companies.

4. Novartis AG v. Union of India (2013) 6 SCC 1

The Supreme Court examined Section 3(d) of the Patents Act in relation to the patent application for a modified form of an existing pharmaceutical substance. Although the case was not an interim injunction decision, it is important in pharmaceutical litigation because it clarifies the statutory standards governing patentability.

5. Bayer Corporation v. Union of India (2014) 60 PTC 277 (Del)

The Delhi High Court considered issues arising from compulsory licensing of the cancer medicine Nexavar. The decision highlights the relationship between pharmaceutical patent rights, public interest and access to affordable medicines.

Challenges in granting interim injunctions

Pharmaceutical injunction disputes involve technical and legal difficulties. Courts may need to examine complex patent claims, scientific evidence, clinical information and competing expert opinions.

Other challenges include:

Balancing patent exclusivity against affordable medicine availability.

Preventing commercially motivated litigation.

Assessing patent validity at an early stage.

Evaluating damages where market competition is restricted.

Avoiding unnecessary delays in access to medicines.

Conclusion

Interim injunction standards in pharmaceutical launches play an important role in balancing patent protection, commercial competition and public health. Indian courts generally apply the tests of prima facie case, balance of convenience and irreparable injury while examining the technical and commercial circumstances of each dispute. Decisions such as Wander Ltd. v. Antox India and F. Hoffmann-La Roche Ltd. v. Cipla Ltd. demonstrate the importance of judicial discretion and public interest. A balanced approach ensures that genuine pharmaceutical innovations receive legal protection without unnecessarily restricting access to affordable medicines.